CN109527123A - A kind of pair of chronic enteritis has the ready-mixed oil of improvement result - Google Patents
A kind of pair of chronic enteritis has the ready-mixed oil of improvement result Download PDFInfo
- Publication number
- CN109527123A CN109527123A CN201811529794.5A CN201811529794A CN109527123A CN 109527123 A CN109527123 A CN 109527123A CN 201811529794 A CN201811529794 A CN 201811529794A CN 109527123 A CN109527123 A CN 109527123A
- Authority
- CN
- China
- Prior art keywords
- ready
- fatty acid
- mixed oil
- oil
- polyunsaturated fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
Abstract
The invention proposes the ready-mixed oils that a kind of pair of chronic enteritis has certain improvement result, it is made including following percentage composition component: the saturated fatty acid that mass percentage is about 31%-35%, the polyunsaturated fatty acid that mass percentage is about 47%-52%, wherein main polyunsaturated fatty acid are as follows: the omega 6 polyunsaturated fatty acid that the omega-3 polyunsaturated fatty acids and mass percentage that mass percentage is about 31%-36% are about 15%-17%.The present invention uses reasonable formula composition, and ready-mixed oil obtained has certain anti-inflammatory effect to chronic enteritis, and patient can be instructed to select the ready-mixed oil for meeting itself state of an illness to eat to improve inflammatory symptom in chronic enteritis period of disease.In addition, ready-mixed oil is daily necessary food materials, has the characteristics that have no toxic side effect compared with drug and can be eaten for a long time, therefore market application value is higher.
Description
Technical field
The present invention relates to edible oil technical fields, and in particular to a kind of pair of chronic enteritis has the ready-mixed oil of improvement result.
Background technique
Enteritis is a kind of using diarrhea as the intestinal inflammatory lesion of main clinical manifestation, can be divided into it is acute with it is chronic.Chronic intestines
Inflammation will lead to Intestinal Mucosal Injury in Patients Undergoing flora imbalance, and continual interaction, makes intestinal mucosa between intestinal tract immune system and enterobacteriaceae
Form a kind of physiological inflammatory conditions.Have that researches show that enteritis disease incidence raised trend, PATIENT POPULATION is mainly in 20-30
Among year and 50-70 years old, and women is compared with male's height, and it was found that the illness rate of chronic enteritis can increase with the increase at age
It is long.Therefore chronic enteritis is a kind of very common disease of digestive system, and clinic is usually based on symptomatic treatment, using Western medicine example
Such as salicylazosulfapyridine Salicylic Acid Formulations treat chronic enteritis, but ineffective and be also easy to produce adverse reaction.In recent years
There are research of many traditional Chinese medicine treatment chronic enteritis, such as shenling baizhu powder treatment chronic enteritis etc., Chinese medicine treats chronic enteritis
Recurrence rate is low, and safety is higher, can be effectively improved prognosis, but Chinese medicine poor taste, is difficult to adhere to taking for a long time and its inconvenience
Place.In addition to this, part Chinese medicine long-term use equally also has adverse reaction, such as: processing of medical material decocts improper, Chinese and Western medicine connection
The adverse reaction of many complexity can be caused with improper and patient's oneself factor.
Fatty acid is the main component of neutral fat, phosphatide and glycolipid, can with unsaturated difference according to hydrocarbon chain saturation
Divide saturated fatty acid, monounsaturated fatty acids and polyunsaturated fatty acid, polyunsaturated fatty acid is generally divided into ω -3 and ω -6
Polyunsaturated fatty acid.Fatty acid is the important nutritional ingredient of needed by human body, and one of important sources are edible oil, for food
Removing requirement with oily people has sufficient amount that can provide the grease of heat, also requires the fatty acid composition basis equalization in grease, with
Meet eucaryotic cell structure and physiological function institute is required, as ready-mixed oil.Have researches show that in fatty acid polyunsaturated fatty acid tool
There are anti-inflammatory effect, especially ω -3 and omega 6 polyunsaturated fatty acid, be able to suppress proinflammatory reaction and adjust immune function, to slow
Property enteritis has the function of preferably restoring health care.We experimentally found that saturated fatty acid, omega-3 polyunsaturated fatty acids
The ready-mixed oil prepared with omega 6 polyunsaturated fatty acid different proportion can play certain therapeutic effect to chronic enteritis, improve
The clinical symptoms of chronic enteritis.Nutrient can be not only provided using the ready-mixed oil as daily food materials for body, and will be chronic enteritis
Patient provides a kind of personalized and can alleviate the state of an illness and make the life better the new way of quality, and market effect is higher.
Summary of the invention
In view of the above problems, the invention proposes a kind of anti-inflammatory ready-mixed oils, use reasonable formula composition, system
The ready-mixed oil aromatic flavour obtained, full of nutrition, safe healthcare especially have preferable antiphlogistic effects to chronic enteritis.
In order to achieve the above purpose, the invention adopts the following technical scheme:
Anti-inflammatory ready-mixed oil, including following percentage composition component are made: saturated fatty acid: polyunsaturated fatty acid=2:3,
Described in polyunsaturated fatty acid are as follows: omega-3 polyunsaturated fatty acids: omega 6 polyunsaturated fatty acid is about 2:1.
Further, the mass percentage of saturated fatty acid is about 31.00%-35.00%, polyunsaturated fatty acid
Mass percentage is about 47.00%-52.00%, wherein being about comprising mass percentage in the polyunsaturated fatty acid
The ω -6 that the omega-3 polyunsaturated fatty acids and mass percentage of 31.00%-36.00% are about 15.00%-17.00% is more
Unsaturated fatty acid.Final prepare becomes comprising saturated fatty acid: omega-3 polyunsaturated fatty acids: ω -6 polyunsaturated fat
Acid is about the edible blend oil that 2:2:1 has anti-inflammatory effect to enteritis.
Compared with existing ready-mixed oil, the invention has the following beneficial effects:
Certain mitigate inflammatory reaction, association for being in the edible for patients of chronic enteritis period of disease this ready-mixed oil and can play
The effect for helping disease treatment, improving quality of life of patients and accelerating the recovery of disease.For enteritis Susceptible population, this ready-mixed oil can
To play certain prevention effect.In addition, ready-mixed oil is daily necessary food materials, has compared with drug and have no toxic side effect and can grow
The feature that phase eats, therefore market application value is higher.
Specific embodiment
In order to make the object, technical scheme and advantages of the embodiment of the invention clearer, below in conjunction with the embodiment of the present invention,
Technical scheme in the embodiment of the invention is clearly and completely described.
Involved vegetable oil includes: walnut oil (the limited public affairs of the vivid blue biotechnology in Shenzhen in the specific embodiment of the invention
Department)；Perilla herb oil (the Shanghai building Ju Xiang Food Co., Ltd)；Wheat-germ oil (Hebei Jia Feng vegetable oil Co., Ltd), coconut oil
(Philippine TEAM ASIA CORPORATION), olive oil (Laiyang Lu Hua heavy fragrant peanut oil Co., Ltd), in every vegetable oil
Fatty acid concrete content it is as shown in table 1.
The different vegetable fatty acids percentage compositions (percentage %) of table 1
Embodiment one
A kind of pair of chronic enteritis has the ready-mixed oil of improvement result, including following percentage composition component is made: perilla oil
55.00%, the ready-mixed oil of wheat-germ oil 10.00%, coconut oil 25.00%, olive oil 10.00%, wherein fatty acid proportion
Are as follows: saturated fatty acid: omega-3 polyunsaturated fatty acids: omega 6 polyunsaturated fatty acid is about 2:2:1.
The saturated fatty acid for being about wherein 31.00% comprising mass percentage in ready-mixed oil, mass percentage are about
31.87% omega-3 polyunsaturated fatty acids, the omega 6 polyunsaturated fatty acid that mass percentage is about 15.57%.
Preparation method are as follows: perilla oil 550kg, wheat-germ oil 100kg, coconut oil 250kg, olive oil 100kg are selected,
It is added in liquid dispenser, is slowly stirred 30min at room temperature, as solute need to unevenly continue stirring until after stirring
Even, then filtering both obtains finished product ready-mixed oil 1000kg.
Embodiment two
A kind of pair of chronic enteritis has the ready-mixed oil of improvement result, including following percentage composition component is made: perilla oil
55.00%, the ready-mixed oil of walnut oil 10.00%, coconut oil 30.00%, olive oil 5.00%, wherein fatty acid proportion are as follows: full
And fatty acid: omega-3 polyunsaturated fatty acids: omega 6 polyunsaturated fatty acid is about 2:2:1.
The saturated fatty acid for being about wherein 33.72% comprising mass percentage in ready-mixed oil, mass percentage are about
32.77% omega-3 polyunsaturated fatty acids, the omega 6 polyunsaturated fatty acid that mass percentage is about 15.62%.
Preparation method are as follows: select perilla oil 550kg, walnut oil 100kg, coconut oil 300kg, olive oil 50kg, be added
Into liquid dispenser, be slowly stirred 30min at room temperature, as stir after solute need to unevenly continue stirring until uniformly, with
After filter both finished product ready-mixed oil 1000kg.
Embodiment three
A kind of pair of chronic enteritis has the ready-mixed oil of improvement result, including following percentage composition component is made: perilla oil
60.00%, the ready-mixed oil of walnut oil 5.00%, wheat-germ oil 5.00%, coconut oil 30.00%, wherein fatty acid proportion are as follows:
Saturated fatty acid: omega-3 polyunsaturated fatty acids: omega 6 polyunsaturated fatty acid is about 2:2:1.
The saturated fatty acid for being about wherein 34.36% comprising mass percentage in ready-mixed oil, mass percentage are about
35.11% omega-3 polyunsaturated fatty acids, the omega 6 polyunsaturated fatty acid that mass percentage is about 16.14%.
Preparation method are as follows: select perilla oil 600kg, walnut oil 50kg, wheat-germ oil 50kg, coconut oil 300kg, add
Enter into liquid dispenser, is slowly stirred 30min at room temperature, if solute need to unevenly continue to stir up to uniform after stirring,
Then filtering both obtains finished product ready-mixed oil 1000kg.
Above embodiments are only to illustrate technical solution of the present invention, and rather than its limitations, embodiments of the present invention are unlimited
It is based on the embodiment of the present invention, obtained by those of ordinary skill in the art without making creative efforts in this
Every other embodiment, shall fall within the protection scope of the present invention, although having carried out with reference to the foregoing embodiments to the present invention detailed
Illustrate, it will be apparent to an ordinarily skilled person in the art that: its still can to technical solution documented by foregoing embodiments into
Row modification or equivalent replacement of some of the technical features；And these are modified or replaceed, and do not make relevant art side
The essence of case departs from the spirit and scope of the technical scheme of various embodiments of the present invention.
Embodiment related experiment result
1. material and method
1.1 reagents and key instrument
Walnut oil (Shenzhen Xu Lan Biotechnology Co., Ltd)；Perilla herb oil (the Shanghai building Ju Xiang Food Co., Ltd)；Wheat
Embryo oil (Hebei Jia Feng vegetable oil Co., Ltd), coconut oil (Philippine TEAM ASIACORPORATION), olive oil (Laiyang
Lu Hua heavy fragrant peanut oil Co., Ltd), dexamethasone (Zhuzhou cent Biotechnology Co., Ltd)；DSS dextran sulfate sodium (beauty
State's MP Biomedicals Products；Molecular weight 36000-50000)；Electronic balance (Hangzhou Wan Te weighing apparatus Co., Ltd)；It is adjacent
Tolidine (Tianjin chemical reagent factory)；Hydrogen peroxide (Beijing Chemical Plant)；Glacial acetic acid (Beijing Chemical Plant).
The preparation of 1.2 ready-mixed oils
The ready-mixed oil prepared in 1 corresponding embodiment one of ready-mixed oil.Preparation method are as follows: select perilla oil 550g, wheat
Bud oil 100g, coconut oil 250g, olive oil 100g, are added in liquid dispenser, are slowly stirred 30min at room temperature, such as stir
Mixing rear solute unevenly need to continue to stir until uniformly, then filtering both obtains finished product ready-mixed oil 1000g.
The ready-mixed oil prepared in 2 corresponding embodiment two of ready-mixed oil.Preparation method are as follows: select perilla oil 550g, walnut oil
100g, coconut oil 300g, olive oil 50g, are added in liquid dispenser, are slowly stirred 30min at room temperature, molten after such as stirring
Matter need to unevenly continue to stir until uniformly, then filtering both obtains finished product ready-mixed oil 1000g.
The ready-mixed oil prepared in 3 corresponding embodiment three of ready-mixed oil.Preparation method are as follows: select perilla oil 600g, walnut oil
50g, wheat-germ oil 50g, coconut oil 300g, are added in liquid dispenser, are slowly stirred 30min at room temperature, such as stir
Solute need to unevenly continue to stir until uniformly, then filtering both obtains finished product ready-mixed oil 1000g afterwards.
1.3 experimental animal
Balb/C mouse, half male and half female, weight (19 ± 3) g are purchased from Dalian Medical Univ's animal experimental center.Random point
For normal group, model group, 1 group of ready-mixed oil, 2 groups of ready-mixed oil, 3 groups of ready-mixed oil, Dexamethasone group (positive control), every group 6.It adjusts
Primary with 3 groups of 1 group of oil, 2 groups of ready-mixed oil, ready-mixed oil daily edible blend oils, dexamethasone is administered in Dexamethasone group intragastric administration on mice,
Continue 35 days, the specific edible way of each group is shown in Table 2.
Table 2: the specific edible way of each group
1.4 chronic enteritis Animal Models
Dextran sulfate sodium (DSS) is dissolved using the drinking water that sterilized, be configured to 3.5% (w/v, i.e., often
3.5g DSS is dissolved into 100mL drinking water) DSS solution, take appropriate solution to be placed in water bottle and be kept in dark place in 4 DEG C, DSS
Matching while using is needed when solution uses every time.Normal group mouse normal diet drinks normal drinking water.To model group, ready-mixed oil
Group, Dexamethasone group mouse freely drink 3.5%DSS solution in the 1-7 days, the 15-21 days, the 29-35 days in experiment, interval
Between change drink normal drinking water, until the 43rd day.From the 1st day ready-mixed oil group edible blend oil, Dexamethasone group intragastric administration on mice was administered,
Normal group, model group feed equal amount of distilled water, until modeling terminates.
The scoring of 1.5 mouse disease activity indexs (DAI)
From the 1st day edible blend oil and dexamethasone gastric infusion, until modeling terminates, each group mouse is observed and recorded
Changes of weight, stool hardness and hematochezia degree, disease activity index (DAI)=(degree score+stool hardness of weight loss
Score+hematochezia degree score)/3, standards of grading are shown in Table 3.
1.5.1 mouse weight
Timing daily takes the mean value measured three times as the same day using electronic balance weighing and record mouse weight (g)
Mouse weight.
1.5.2 stool hardness
According to same daily by same gauger to the classification of excrement stickiness (normal, loose and diarrhea) in DAI scoring
The excrement of one time record and observation mouse.
1.5.3 benzidine fecal occult blood experiment investigation mouse hematochezia situation
O-tolidine fecal occult blood reagent:
1) 1% o-tolidine glacial acetic acid reagent: glacial acetic acid and each 50mL of ethyl alcohol, dissolution is added in o-tolidine 1.00g
Postposition brown bottle is stored in 4 DEG C of refrigerators.
2) 3% hydrogenperoxide steam generator: 30% hydrogenperoxide steam generator 10mL adds distilled water to be settled to 100mL, sets brown bottle guarantor
It deposits.
Take a small amount of excrement among glass plate with cotton swab, be added dropwise the 1% benzidine glacial acetic acid solution 2-3 drop for preparing in advance in
On excrement, be added dropwise 3% hydrogenperoxide steam generator 2-3 drop, immediately observation as a result, in 2min show blue for the positive (occult blood),
It does not develop the color still after 2min for feminine gender.
Table 3: disease activity index (DAI) standards of grading
1.6 mouse colitis anatomical lesion scores
Each group mouse conscientiously observes the general form of colon intestinal tube after putting to death in the 43rd day, and longitudinally splits intestinal tube, observes
Mucous membrane is congested, oedema degree and situations such as whether there is or not blutpunktes, degree of injury and model according to Morris standards of grading assessment colon
It encloses and is shown in Table 4.
Table 4: colitis anatomical lesion scoring
1.7 statistics and analysis
All experimental datas useIt indicates, one-way analysis of variance, P < 0.05 is carried out to data with SPSS19.0
With statistical significance.
2. experimental result
The influence that 2.1 ready-mixed oils score to mouse disease activity index (DAI)
Without death, model group mouse body weight increases obvious for normal group, model group, ready-mixed oil group and Dexamethasone group mouse
It is slower than normal group, difference is statistically significant (P < 0.05), shows modeling success.Preceding 14 days ready-mixed oil groups and Dexamethasone group phase
Than in model group, group difference is not statistically significant (P > 0.05), but since the 15th day ready-mixed oil group compared with model group
There is raised trend, difference is statistically significant (P < 0.05), shows mouse enteritis caused by ready-mixed oil energy relative remission DSS.
Ready-mixed oil 1, ready-mixed oil 2,3 groups of ready-mixed oil of mouse weight change no significant difference, it is believed that saturated fatty acid, ω -3
Polyunsaturated fatty acid and omega 6 polyunsaturated fatty acid total content are in 78.71%-86.04%, and three's content ratio is 2:
When 2:1, there is no difference to the curative effect of chronic enteritis.Specific data are shown in Table 5.Excrement observation display is normal to organize excrement substantially just
Often, no occult blood and naked eyes bloody stool；Model group excrement is soft and loose, the occult blood positive occurs within the 5th day, naked eyes bloody stool occurs within the 7th day, it
After continue to drinking-water 2-3 days, bloody stool gradually improves, and ready-mixed oil group fecal character is normal, part soft stool, and the goes out for 6-7 days
Existing occult blood is positive, and hematochezia is light compared with model group, and Dexamethasone group fecal character is normal, and part occurs the occult blood positive on the 7th day, just
Blood is light compared with model group.According to data assessment DAI, as the result is shown compared with normal group, the DAI value of model group mouse is apparently higher than just
Normal group, difference all has statistical significance (P < 0.05), shows modeling success.Compared with model group, the DAI of ready-mixed oil group mouse
Value is below model group, and difference all has statistical significance (P < 0.05), illustrates that ready-mixed oil alleviates the inflammatory reaction in enteron aisle,
Reduce intestinal cell membrane permeability, reduces cell liquid exudation, and then alleviate murine chronic enteritis caused by DSS.Ready-mixed oil
1, ready-mixed oil 2,3 groups of ready-mixed oil of DAI value, without significant difference, it is believed that saturated fatty acid, ω -3 polyunsaturated fat
Acid and omega 6 polyunsaturated fatty acid total content are in 78.44%-85.61%, and when three's content ratio is 2:2:1, to slow
The curative effect of property enteritis does not have difference.Specific data are shown in Table 6.
Table 5: the daily average weight variation (%) of groups of animals
#P < 0.05 is compared with normal group；*P < 0.05 is compared with model group；Ready-mixed oil is compared with Dexamethasone group
Table 6: disease activity index (DAI) scoring of each group mouse
#P < 0.05 is compared with normal group；*P < 0.05 is compared with model group；Ready-mixed oil is compared with Dexamethasone group
The influence that 2.2 ready-mixed oils score to mouse colitis anatomical lesion
As shown in table 7, the colitis anatomical lesion scoring of model group mouse is apparently higher than normal group, and difference has statistics
Meaning (P < 0.05) shows modeling success.Compared to model group, the colitis anatomical lesion scoring of ready-mixed oil group mouse is
Decline, difference have statistical significance (P < 0.05), illustrate that ready-mixed oil can alleviate the inflammation of mouse intestinal to a certain extent
Damage.Ready-mixed oil 1, ready-mixed oil 2, the scoring of 3 groups of ready-mixed oil of colitis anatomical lesion, without significant difference, it is believed that full
With fatty acid, omega-3 polyunsaturated fatty acids and omega 6 polyunsaturated fatty acid total content in 78.44%-85.61%, and three
When person's content ratio is 2:2:1, there is no difference to the curative effect of chronic enteritis, specific data are shown in Table 7.
Table 7: the colitis anatomical lesion scoring of each group
#P < 0.05 is compared with normal group；*P < 0.05 is compared with model group；Ready-mixed oil is compared with Dexamethasone group
3. conclusion
This experiment discovery, compared with dexamethasone positive controls, although ready-mixed oil each group is to the anti-inflammatory effect of chronic enteritis
Fruit is not so good as dexamethasone, but a degree of inflammatory reaction for mitigating chronic enteritis of ready-mixed oil 1, ready-mixed oil 2, ready-mixed oil 3 energy,
Play certain improvement result.It is well known that ready-mixed oil is daily necessary food materials, has compared with drug and have no toxic side effect and can grow
The characteristics of phase takes, therefore can be used for the prevention and treatment of chronic enteritis, market application value is higher.
Claims (2)
1. the ready-mixed oil that a kind of pair of chronic enteritis has improvement result, it is characterised in that: the ready-mixed oil includes that quality percentage contains
Amount is the saturated fatty acid of 31%-35%, and mass percentage is the polyunsaturated fatty acid of 47%-52%, wherein more insatiable hungers
With in fatty acid include mass percentage be 31%-36% omega-3 polyunsaturated fatty acids and mass percentage be
The omega 6 polyunsaturated fatty acid of 15%-17%, final prepare become comprising saturated fatty acid: omega-3 polyunsaturated fatty acids:
Omega 6 polyunsaturated fatty acid is the edible blend oil of 2:2:1.
2. pair chronic enteritis has application of the ready-mixed oil of improvement result in the food for improving chronic enteritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811529794.5A CN109527123A (en) | 2018-12-14 | 2018-12-14 | A kind of pair of chronic enteritis has the ready-mixed oil of improvement result |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811529794.5A CN109527123A (en) | 2018-12-14 | 2018-12-14 | A kind of pair of chronic enteritis has the ready-mixed oil of improvement result |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109527123A true CN109527123A (en) | 2019-03-29 |
Family
ID=65855064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811529794.5A Pending CN109527123A (en) | 2018-12-14 | 2018-12-14 | A kind of pair of chronic enteritis has the ready-mixed oil of improvement result |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109527123A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434183A (en) * | 1991-05-30 | 1995-07-18 | Pharmacia Ab | Phospholipids containing omega-3-fatty acids |
| JPH0971530A (en) * | 1995-09-06 | 1997-03-18 | Snow Brand Milk Prod Co Ltd | Agent for treatment of inflammatory intestinal disease |
| CN1282223A (en) * | 1997-12-23 | 2001-01-31 | 利尔生公司 | Fat blend |
| WO2007057511A1 (en) * | 2005-11-18 | 2007-05-24 | Raisio Oyj | Improved fat composition |
| CN1997290A (en) * | 2004-06-22 | 2007-07-11 | 努特里希亚公司 | Improvement of intestinal barrier integrity |
| US20090238893A1 (en) * | 2006-06-26 | 2009-09-24 | Jane Elizabeth Langford | Nutritional formulation |
| US20120264832A1 (en) * | 2011-04-17 | 2012-10-18 | Gurin Michael H | Low Inflammatory Blended Oils |
| CN106819154A (en) * | 2016-11-30 | 2017-06-13 | 王维义 | Formula oil of a kind of omega 3,6,9 and preparation method thereof |
| CN107105745A (en) * | 2014-11-07 | 2017-08-29 | 马修·乔利·瓦达科姆里 | The nutrient fat acid composition of optimization |
| CN108601807A (en) * | 2016-02-16 | 2018-09-28 | Atp研究有限公司 | Preparation and application method |
-
2018
- 2018-12-14 CN CN201811529794.5A patent/CN109527123A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434183A (en) * | 1991-05-30 | 1995-07-18 | Pharmacia Ab | Phospholipids containing omega-3-fatty acids |
| JPH0971530A (en) * | 1995-09-06 | 1997-03-18 | Snow Brand Milk Prod Co Ltd | Agent for treatment of inflammatory intestinal disease |
| CN1282223A (en) * | 1997-12-23 | 2001-01-31 | 利尔生公司 | Fat blend |
| CN1997290A (en) * | 2004-06-22 | 2007-07-11 | 努特里希亚公司 | Improvement of intestinal barrier integrity |
| WO2007057511A1 (en) * | 2005-11-18 | 2007-05-24 | Raisio Oyj | Improved fat composition |
| US20090238893A1 (en) * | 2006-06-26 | 2009-09-24 | Jane Elizabeth Langford | Nutritional formulation |
| US20120264832A1 (en) * | 2011-04-17 | 2012-10-18 | Gurin Michael H | Low Inflammatory Blended Oils |
| CN107105745A (en) * | 2014-11-07 | 2017-08-29 | 马修·乔利·瓦达科姆里 | The nutrient fat acid composition of optimization |
| CN108601807A (en) * | 2016-02-16 | 2018-09-28 | Atp研究有限公司 | Preparation and application method |
| CN106819154A (en) * | 2016-11-30 | 2017-06-13 | 王维义 | Formula oil of a kind of omega 3,6,9 and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| HAGI, A等: "Effects of the omega-6:omega-3 Fatty Acid Ratio of Fat Emulsions on the Fatty Acid Composition in Cell Membranes and the Anti-Inflammatory Action", 《JOURNAL OF PARENTERAL AND ENTERAL NUTRITION》 * |
| SAINI, RK等: "Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance - A review", 《LIFE SCIENCES》 * |
| 王晓菲等: "基于脂肪酸探讨调和油对小鼠过敏性疾病的治疗作用", 《药物评价研究》 * |
| 田玉玲等: "不同比例ω-3/ω-6多不饱和脂肪酸对大鼠慢性结肠炎模型的影响", 《解放军医学院学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5335192B2 (en) | Novel dietary supplement composition and use thereof | |
| CN108703180A (en) | A kind of high fibre, low-carbon, life ketone biscuit and preparation method thereof high in fat | |
| CN107136511A (en) | A kind of peony seed oil composition for promoting cranial nerve development, Peony-seed-oil soft capsule and preparation method thereof | |
| CN101999666A (en) | Health-care product composition for improving vision and preparation method thereof | |
| DE602004006860T2 (en) | CAPSAICINOID-CONTAINING PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
| CN107683909A (en) | The special ready-mixed oil of high fat diet | |
| CN105168308A (en) | Altitude sickness-resistant compound Tibetan medicine preparation | |
| CN105053617A (en) | High-nutrient dietary-fiber feed for duck and preparation method thereof | |
| CN105341946A (en) | Dunaliella salina, lutein and huckleberry composition, soft capsule containing composition and preparation method of soft capsule | |
| CN106720469A (en) | Edible modulation oil of one kind and preparation method thereof | |
| CN109527123A (en) | A kind of pair of chronic enteritis has the ready-mixed oil of improvement result | |
| CN106389740A (en) | Composition for preventing and/or delaying old people with mild cognitive impairment and use method thereof | |
| Schleicher et al. | Black cumin: the magical Egyptian herb for allergies, asthma, and immune disorders | |
| CN101716187A (en) | Oral liquid for promoting lead discharge and strengthening immunity and preparation method thereof | |
| CN106819223A (en) | A kind of health-care milk tea and preparation method thereof | |
| CN103704349A (en) | Donkey milk powder formula based on medicine food homology | |
| RU2306719C1 (en) | Method for improving of individual's health | |
| Ball | The Female Physician: Or, Every Woman Her Own Doctress: Wherein is Summarily Comprised, All that is Necessary to be Known in the Cure of the Several Disorders to which the Fair Sex are Liable; Together with Prescriptions in English... By John Ball, MD... | |
| TW200305429A (en) | Use of a mare's milk concentrate dried on a biologically inert, highly-disperse matrix | |
| JPWO2018221627A1 (en) | Processed product of purslane, Processed product of purslane, supplement, pharmaceutical, intestinal mucosa protective agent and intestinal regulator | |
| Gallup Jr et al. | Evolutionary medicine: the impact of evolutionary theory on research, prevention, and practice | |
| Myers | Symptoms of Diseases | |
| JP2010100576A (en) | Constipation-improving agent | |
| Bhattacharyya | Carcinoma And Carcinosin | |
| CN106387326A (en) | Piggy feed capable of resisting diarrhoea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190329 |
|
| RJ01 | Rejection of invention patent application after publication |